http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014506888-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2011-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2014506888-A |
| titleOfInvention | A method for treating breast cancer by reducing adenine nucleotide transfector 2 mRNA expression |
| abstract | A composition for treating breast cancer, a method for treating breast cancer stem cells, and the like are provided. The present invention relates to a method of treating breast cancer by reducing ANT2 mRNA expression. Specifically, the present invention provides a composition for treating breast cancer containing ANT2 siRNA or ANT2 shRNA as an active ingredient, which is characterized by suppressing breast cancer cell metastasis. The composition of the present invention is characterized by increasing the therapeutic effect of TRAIL on breast cancer. The present invention also provides a composition for treating breast cancer stem cells containing ANT2 siRNA or ANT2 shRNA as an active ingredient. Extremely, the present invention can provide a breast cancer therapeutic agent having excellent efficacy capable of overcoming the metastasis inhibitory effect and anticancer drug resistance of breast cancer cells. It is expected that it can be used. [Selection] Figure 14 |
| priorityDate | 2011-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 469.